Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation 金斯瑞生物科技股份有限公司 \* (Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1548)

## VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS

This announcement is made by Genscript Biotech Corporation (the "Company") on a voluntary basis.

The board of directors of the Company (the "**Board**") has noted the recent increases in the price and trading volume of the shares of the Company.

Having made such enquiries with respect to the Company as is reasonable in the circumstances, the Board confirms that, as of the time of this announcement, it is not aware of any reasons for these share price or trading volume movements, and it is not aware of any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

This announcement is made by the order of the Company. The Board collectively and individually accepts responsibility for the accuracy of this announcement.

Shareholders and potential investors of the Company are advised to exercise caution when dealing with the shares of the Company.

By order of the Board GenScript Biotech Corporation MENG Jiange Chairman and Executive Director

Hong Kong, 15 July 2024

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Director is Dr. Wang Luquan; and the independent non-executive Directors are Mr. Dai Zumian, Mr. Pan Jiuan, Mr. Cheung Yiu Leung Andy and Dr. Shi Chenyang.

\* For identification purposes only